Welcome to Hymovis Sites. This is your first post. Edit or delete it, then start writing!
1. Bonnevie ED, Galesso D, Secchieri C, Bonassar LJ. Frictional characterization of injectable hyaluronic acids is more predictive of clinical outcomes than traditional rheological or viscoelastic characterization. PLOS One. 2019 May 10;14(5):e0216702. 2. Finelli I, Chiessi E, Galesso D, Renier D, Paradossi G. A new viscosupplement based on partially hydrophobic hyaluronic acid: a comparative study. Biorheology. 2011;48(5):263-75. 3. Data on file, Fidia Farmaceutici S.P.A., Italy. 4. HYMOVIS® [package insert]. Fidia Farmaceutici S.P.A. Abano Terme, Italy 2017. 5. Bisicchia S, Bernardi G, Tudisco C. HYMOVIS® (HYADD® 4) versus methylprednisolone acetate in symptomatic knee osteoarthritis: a single-centre single blind prospective randomised controlled clinical study with a 1-year follow-up. Clin Exp Rheumatol. 2016;34(5):857-863. 6. Priano F. Early Efficacy of Intra-Articular HYADD® 4 (HYMOVIS®) Injections for Symptomatic Knee Osteoarthritis. Joints. 2017 Jul 28;5(2):79-84. 7. Benazzo F, Perticarini L, Padolino A, et al. A multi-centre, open-label, long-term follow-up study to evaluate the benefits of a new viscoelastic hydrogel (HYMOVIS®) in the treatment of knee osteoarthritis. Eur Rev Med Pharmacol Sci. 2016;20:959-968.
Single-center, single blind prospective, randomized controlled clinical study
To compare clinical results. quality of life, and safety achieved by intra-articular (IA) injections of HYMOVIS® versus an IA corticosteroid (methylprednisolone acetate) in the treatment of symptomatic knee OA
Ambulatory male and female patients (N=150, > 45 years of age) with unilateral symptomatic primary knee OA
WOMAC total scores at 26 weeks
Prospective, multi-center, open-label, clinical study with 52-week follow-up
To evaluate the long-term efficacy and safety of HYMOVIS® in the treatment of symptomatic osteoarthritis (OA) of the knee
Patients (age >40 years) with clinically and radiologically confirmed knee OA and a complaint of pain in the target knee (N = 49)
Knee OA pain, measured by WOMAC A (pain) over 52 weeksa
The aim of the study was to evaluate the clinical efficacy and safety of HYMOVIS® (HYADD® 4), a hydrogel based on a hyaluronic acid derivative, in patients with symptomatic knee osteoarthritis
aData obtained from the ANTIAGE National Registry (Italy): Associazione Nazionale por la Terapia Intra Articcolare con Guida Ecografica (ANTIAGE) - A nonprofit database of clinical data on effects of ultrasound-guided intra-articular viscosupplementation
One reply on “Hello world!”
Hi, this is a comment.
To get started with moderating, editing, and deleting comments, please visit the Comments screen in the dashboard.
Commenter avatars come from Gravatar.